In this interview from the ARVO 2013 Annual Meeting, Dr. Paul Chan explains how online education and telemedicine help clinicians abroad manage patients at risk of retinopathy of prematurity (ROP). As the incidence of ROP increases worldwide, neonatal services are pressed to screen for ROP and treat infants diagnosed with the disease. But the window for treatment is usually no more than 3 days, and if missed on diagnosis, progressive disease results in substantial or total vision loss. The most critical issue, says Dr. Chan, is education. He works with several university and nonprofit groups to provide web-based resources and remote screening services for sites around the world. Dr. Chan also discusses the role and safety of anti-VEGF therapy in treating ROP, and a new Academy web initiative to serve region- and disease-specific educational needs of the global ophthalmic community.